579 related articles for article (PubMed ID: 26078391)
21. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth.
Ohta T; Iijima K; Miyamoto M; Nakahara I; Tanaka H; Ohtsuji M; Suzuki T; Kobayashi A; Yokota J; Sakiyama T; Shibata T; Yamamoto M; Hirohashi S
Cancer Res; 2008 Mar; 68(5):1303-9. PubMed ID: 18316592
[TBL] [Abstract][Full Text] [Related]
22. Battles against aberrant KEAP1-NRF2 signaling in lung cancer: intertwined metabolic and immune networks.
Xu K; Ma J; Hall SRR; Peng RW; Yang H; Yao F
Theranostics; 2023; 13(2):704-723. PubMed ID: 36632216
[TBL] [Abstract][Full Text] [Related]
23. PAQR4 promotes chemoresistance in non-small cell lung cancer through inhibiting Nrf2 protein degradation.
Xu P; Jiang L; Yang Y; Wu M; Liu B; Shi Y; Shen Q; Jiang X; He Y; Cheng D; Xiong Q; Yang Z; Duan L; Lin J; Zhao S; Shi P; Yang C; Chen Y
Theranostics; 2020; 10(8):3767-3778. PubMed ID: 32206121
[No Abstract] [Full Text] [Related]
24. Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
Cai MC; Chen M; Ma P; Wu J; Lu H; Zhang S; Liu J; Zhao X; Zhuang G; Yu Z; Fu Y
Int J Cancer; 2019 Feb; 144(4):788-801. PubMed ID: 30411339
[TBL] [Abstract][Full Text] [Related]
25. Role of the Keap1-Nrf2 pathway in cancer.
Leinonen HM; Kansanen E; Pölönen P; Heinäniemi M; Levonen AL
Adv Cancer Res; 2014; 122():281-320. PubMed ID: 24974185
[TBL] [Abstract][Full Text] [Related]
26. ROS‑mediated hypomethylation of PRDX5 promotes STAT3 binding and activates the Nrf2 signaling pathway in NSCLC.
Cao X; Chen XM; Xiao WZ; Li B; Zhang B; Wu Q; Xue Q
Int J Mol Med; 2021 Feb; 47(2):573-582. PubMed ID: 33416106
[TBL] [Abstract][Full Text] [Related]
27. Keap1 Inhibits Metastatic Properties of NSCLC Cells by Stabilizing Architectures of F-Actin and Focal Adhesions.
Wu B; Yang S; Sun H; Sun T; Ji F; Wang Y; Xu L; Zhou D
Mol Cancer Res; 2018 Mar; 16(3):508-516. PubMed ID: 29330291
[TBL] [Abstract][Full Text] [Related]
28. Nrf2/P-glycoprotein axis is associated with clinicopathological characteristics in colorectal cancer.
Sadeghi MR; Jeddi F; Soozangar N; Somi MH; Shirmohamadi M; Khaze V; Samadi N
Biomed Pharmacother; 2018 Aug; 104():458-464. PubMed ID: 29793178
[TBL] [Abstract][Full Text] [Related]
29. Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma.
Mahaffey CM; Mahaffey NC; Holland W; Zhang H; Gandara DR; Mack PC; Forman HJ
J Thorac Oncol; 2012 Jan; 7(1):34-9. PubMed ID: 22089114
[TBL] [Abstract][Full Text] [Related]
30. Functional dissection of Nrf2-dependent phase II genes in vascular inflammation and endotoxic injury using Keap1 siRNA.
Kim JH; Choi YK; Lee KS; Cho DH; Baek YY; Lee DK; Ha KS; Choe J; Won MH; Jeoung D; Lee H; Kwon YG; Kim YM
Free Radic Biol Med; 2012 Aug; 53(3):629-40. PubMed ID: 22609006
[TBL] [Abstract][Full Text] [Related]
31. Methylseleninic acid activates Keap1/Nrf2 pathway via up-regulating miR-200a in human oesophageal squamous cell carcinoma cells.
Liu M; Hu C; Xu Q; Chen L; Ma K; Xu N; Zhu H
Biosci Rep; 2015 Sep; 35(5):. PubMed ID: 26341629
[TBL] [Abstract][Full Text] [Related]
32. [Nrf2 down-regulated cell line H460-N5 with Keap1 over-expression increased sensitivity to anti-cancer drugs].
Qu LY; Gao P; Wang HY; Wang XJ; Tang XW
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 Jan; 39(1):6-10. PubMed ID: 20175229
[TBL] [Abstract][Full Text] [Related]
33. The oncoprotein HBXIP competitively binds KEAP1 to activate NRF2 and enhance breast cancer cell growth and metastasis.
Zhou XL; Zhu CY; Wu ZG; Guo X; Zou W
Oncogene; 2019 May; 38(21):4028-4046. PubMed ID: 30692632
[TBL] [Abstract][Full Text] [Related]
34. ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer.
Vartanian S; Lee J; Klijn C; Gnad F; Bagniewska M; Schaefer G; Zhang D; Tan J; Watson SA; Liu L; Chen H; Liang Y; Watanabe C; Cuellar T; Kan D; Hartmaier RJ; Lau T; Costa MR; Martin SE; Merchant M; Haley B; Stokoe D
Cancer Res; 2019 Oct; 79(19):4828-4839. PubMed ID: 31416841
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of miR-200a protects cardiomyocytes against hypoxia-induced apoptosis by modulating the kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2 signaling axis.
Sun X; Zuo H; Liu C; Yang Y
Int J Mol Med; 2016 Oct; 38(4):1303-11. PubMed ID: 27573160
[TBL] [Abstract][Full Text] [Related]
36. Molecular regulation of S100P in human lung adenocarcinomas.
Rehbein G; Simm A; Hofmann HS; Silber RE; Bartling B
Int J Mol Med; 2008 Jul; 22(1):69-77. PubMed ID: 18575778
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-7 activates Nrf2 pathway by targeting Keap1 expression.
Kabaria S; Choi DC; Chaudhuri AD; Jain MR; Li H; Junn E
Free Radic Biol Med; 2015 Dec; 89():548-56. PubMed ID: 26453926
[TBL] [Abstract][Full Text] [Related]
38. UHRF1 regulation of the Keap1-Nrf2 pathway in pancreatic cancer contributes to oncogenesis.
Abu-Alainin W; Gana T; Liloglou T; Olayanju A; Barrera LN; Ferguson R; Campbell F; Andrews T; Goldring C; Kitteringham N; Park BK; Nedjadi T; Schmid MC; Slupsky JR; Greenhalf W; Neoptolemos JP; Costello E
J Pathol; 2016 Feb; 238(3):423-33. PubMed ID: 26497117
[TBL] [Abstract][Full Text] [Related]
39. Oncogenic KEAP1 mutations activate TRAF2-NFκB signaling to prevent apoptosis in lung cancer cells.
Deen AJ; Adinolfi S; Härkönen J; Patinen T; Liu X; Laitinen T; Takabe P; Kainulainen K; Pasonen-Seppänen S; Gawriyski LM; Arasu UT; Selvarajan I; Mäkinen P; Laitinen H; Kansanen E; Kaikkonen MU; Poso A; Varjosalo M; Levonen AL
Redox Biol; 2024 Feb; 69():103031. PubMed ID: 38184997
[TBL] [Abstract][Full Text] [Related]
40. [CXCR4 and Nrf2 expressions in non-small cell lung cancer and their clinical implications].
Hu T; Yao Y; Yu S; Guo H; Tian T; Han L; Wang W; Guo Q; Wang J; Nan K; Wang S
Nan Fang Yi Ke Da Xue Xue Bao; 2014 Feb; 34(2):153-8. PubMed ID: 24589587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
